retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide is a triple agonist

In one trial where participants did not use CPAP, Zepbound reduced AHI events by an average of 25 per hour after one year, compared to a reduction of just five events in the placebo group

Time your meals to support stable energy throughout the day, eating smaller portions every 34 hours rather than skipping meals

When taking empagliflozin with other prescription medications, over-the-counter medications, and vitamins, a healthcare professional can provide advice on how to combine them safely

There were several study limitations identified by the researchers

No, but even light activity helps maximize fat loss and prevent muscle loss

Full text Jastreboff AM, et al